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Abstract 
Purpose of Review: To highlight recent breakthroughs and controversies in the use of 
myoblast models to uncover cellular and molecular mechanisms regulating skeletal 
muscle hypertrophy and atrophy.   
Main Findings: Myoblast cultures provide key mechanistic models of the signalling 
and molecular pathways potentially employed by skeletal muscle in-vivo to regulate 
hypertrophy and atrophy. Recently the controversy as to whether IGF-I is important in 
hypertrophy following mechanical stimuli vs. alternative pathways has been hotly 
debated and is discussed. The role of myostatin in myoblast models of atrophy, and 
interactions between protein synthetic pathways including Akt/mTOR and the 
‘atrogenes’ are explored.  
Summary: Targeted in-vivo experimentation directed by skeletal muscle cell culture 
and bioengineering (3-dimensonal skeletal muscle cell culture models) will provide 
key biomimetic and mechanistic data regarding hypertrophy and atrophy and thus 
enable the development of important strategies for tackling muscle wasting associated 
with ageing and disease processes.  
 
Keywords: muscle precursor cell, satellite cell, IGF-I, myostatin, 3D muscle 
constructs. 
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Introduction: The use of Myoblast Models to Investigate Mechanisms of Skeletal 
Muscle Size Regulation 
Adult skeletal muscle fibre number is set in-utero and adult fibres are terminally 
differentiated or incapable of division. Despite these phenomena, adult skeletal 
muscle is highly adaptable, responding to the soluble and biophysical cues that it 
encounters on a daily basis. Skeletal muscle undergoes rapid growth (hypertrophy) 
during development, exercise, stretch and mechanical loading (weight bearing) and 
also severe loss (atrophy) with ageing, disuse and disease. It is also capable of repair 
and regeneration following injury. Much of this adaptability (growth and repair) is 
achieved via resident adult stem cells, termed satellite or muscle precursor cells 
(MPC) that have mitotic potential. Recent data suggest that blocking myostatin (a 
negative regulator of muscle mass), enables hypertrophy not only via satellite cell 
accretion but also via increased modulation of the synthesis and turnover of structural 
proteins within a myotube/fibre (1)*.  
 
Satellite cells are fundamental to muscle adaptation; they are specialised cells, 
normally residing in a quiescent state beneath the basal lamina of myofibres.  
Following physiological, bio-mechanical or pathological cues, they are activated to 
myoblasts and become committed to the muscle/mesenchymal linage, adopting not 
only a muscle phenotype, but given relevant cues, also neural (2), osteoblast (3, 4), 
chrondocyte (5) and adipocyte (6) linages. In order to elicit reparative responses, 
satellite cells must i. be activated, ii. increase their numbers (proliferation), iii. 
migrate to the site of injury and iv. fuse (differentiate) with the damaged fibre (7). 
Because of their fundamental roles in muscle maintenance and adaptation, myoblasts 
are frequently studied as in-vitro models of growth, migration, differentiation and 
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death. Basal, hypertrophic or atrophic conditions are used and provide relevant 
models of muscle growth (exercise and puberty) or wasting in catabolic conditions 
(e.g. cancer, AIDS, congestive heart failure, sepsis, COPD, rheumatoid arthritis and 
sarcopenia (muscle wasting associated with ageing)). These myoblast models use 
either primary skeletal muscle cells derived from human or animal biopsies, or, more 
frequently, established cell lines such as the mouse C2, C2C12 (a clonal derivative and 
daughter of the C2 cells), or rat L6 cells. Advantages of cell lines vs. primary human 
culture include: Availability, ethics, reduced cost, access to cells, speed of growth and 
pure myogenic populations. Disadvantages of muscle cultures vs. in-vivo models 
include: Reduced differentiation capacity with passage, an inability to sustain 
myotubes for extended periods in culture and the environment of 2-D monolayer that 
lacks bio-mimicity, thus making direct comparisons with muscle in-vivo difficult. 
Development and manipulation of models using both collagen and fibrin gels to 
incorporate a 3-Dimensional (3-D) structure for myoblasts in culture (8)**(9) will 
potentially enable more physiological experimentation and analyses of the regulators 
of hypertrophy and atrophy.  
 
This review will therefore highlight the most recent breakthroughs in the use of 
myoblasts as models to investigate and manipulate cellular and molecular regulators 
of hypertrophy and atrophy. Given the nature of this review, in-vivo data will be 
reported only to portray the relevance of the in-vitro findings. 
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Myoblast Models of Hypertrophy: Insulin-like Growth-Factors (IGFs) versus 
Mechano-Transduction. 
Insulin-like Growth Factors (IGFs) influence hypertrophy of skeletal muscle primary 
and cell line cultures, enhancing proliferation, differentiation (reviewed in (10)), 
survival (11), satellite cell recruitment (12) and myofibrillar protein accretion (13). 
Despite high levels of systemic liver-derived IGF, a recent in-vivo study suggests that 
local production of IGF-I by skeletal muscle is imperative in hypertrophy. Where 
liver deficient IGF-I mice demonstrate similar strength gains to controls with larger 
increases in IGF-I receptor tyrosine phosphorylation (14) and associated 
PI3K/Akt/mTOR induced protein synthesis (14). Despite these compelling data, the 
importance of IGF-I in mechanical load (weight bearing) induced hypertrophy has 
recently been debated (15, 16)**. Never the less, the withdrawal of serum in-vitro is 
sufficient to induce myoblast differentiation in both cell lines and primary cultures 
which are able to produce endogenous IGF-I that facilitates the fusion process (17)**, 
furthermore, supplementation with IGF-I augments hypertrophy compared with basal 
conditions (18-20). Validation of the mechanisms pertaining to IGF, hypertrophy and 
mechanical load in-vivo therefore continues and would be facilitated by an in-vitro 
model that incorporates mechanical load. A recent study, using stretch, illustrated that 
primary chick myotubes undergo significant hypertrophy following activation of the 
PI3K/Akt/mTOR pathways (which lie downstream of IGF-I/IGF-IR activation). 
Hypertrophy was also prevented using pharmacological inhibitors of PI3K and mTOR 
(21), however, the authors did not measure endogenous production of IGF-I. 
Therefore, explicit confirmation of the role of IGF in these models is awaited.  
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Mechano-Transduction Signalling 
The mammalian target of rapamycin, mTOR, can be activated via signals independent 
of IGF-I, via a pathway involving phospholipase D (PLD), phosphatidic acid and a 
downstream regulator Rheb (ras homologue enriched brain) (see (22-24). 
Furthermore, mTOR can be stimulated via amino acids, particularly leucine (25, 26), 
potentially via Rheb binding and interaction with amino acid sensitive 
phosphatidylinositol 3-kinase/Vps34 (24) or MAP4K3 (27). The stress response gene 
Redd 2, may also be important in inhibiting mTOR via the tuberous sclerosis 1 
(TSC1) and 2 (TSC2) complex (28), and following mechanical overload Redd 2 is 
reduced to enable mTOR to initiate p70S6K expression, which is involved in protein 
synthesis and hypertrophy (29) (see Figure 1). To substantiate that mechanical signals 
can operate independently of IGF-I signalling; in-vivo evidence from Spangenburg et 
al. (30)** suggests that mice overexpressing a dominant negative form of IGF-IR 
(MKR mice), elicited similar hypertrophic responses, following synergistic ablation 
of the plantaris muscle compared to wild-type mice. Suggesting that IGF-I is not 
required for load-induced hypertrophy. By contrast, Heron-Milhavet et al. (31)** also 
using the MKR mouse showed IGF-I to be fundamental in myoblast fusion, with 
primary MKR myoblasts showing impaired differentiation, versus wild-type controls, 
following damage (31). Interestingly, MKR-derived muscle cells had equivalent 
levels of myogenin (a myogenic regulatory factor fundamental to lineage and 
hypertrophy) positive cells to wild type. However, the ability of the myogenin 
positive cells to fuse into multinucleated myotubes was significantly lower in MKR 
vs. wild-type-derived myoblasts. Indeed, a significantly greater proportion of fusion-
hampered MKR-derived myoblasts compared with control cells (31), suggests that 
IGF-I does play an influential role in differentiation and hypertrophy but that other 
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factors enable hyperplasia. Although data from Spangenburg et al. (30) appear to 
contradict the observations by Heron-Milhavet et al. (31), different modes of 
hypertrophy were being examined. Spangenburg et al. (30) performed no cellular or 
histological analyses, thus questioning whether the increase in muscle mass observed 
in MKR mice (similar to controls) corresponded to a true hypertrophic vs. 
hyperplastic responses.  
 
A Biphasic Role for IGF-I? 
Utilising an in-vitro model of hypertrophy and atrophy (comparing younger 
phenotypes of clonally derived daughter C2C12 vs. parental C2 cells), we have recently 
published that IGF-I is important for the greater differentiation potential of C2C12 vs. 
C2 cells (17)**. Importantly, IGF-I expression was similar at 48 hrs following 
initiation of differentiation in both cell types, despite greater morphological 
differentiation in the C2C12 cells. By 72 hrs, however, IGF-I expression was 
significantly greater in C2C12 vs. C2 cells as were morphological and biochemical 
differentiation. These data indicate a potential biphasic role for IGF in underpinning 
the temporal complexity of differentiating myoblasts. Despite similar levels of IGF-I 
expression at 48 hrs, reductions in myoD and myogenin were evident in the C2 vs. 
C2C12 cells and this may underpin the reduced potential for differentiation of these 
cells. Finally, an inverse expression pattern of IGF binding protein-2 (IGFBP2) was 
evident in the two cell types. The role for IGFBP2 warrants further investigation as it 
may be crucial in modulating IGF-induced differentiation especially with age (17)**. 
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Other Potential Hypertrophic Mechanisms  
A recent study, using a single fibre approach, suggested that extracellular matrix and 
fibroblasts are fundamental for muscle hypertrophy, enabling increases in hepatocyte 
growth factor (HGF) expression. HGF binds to the c-met receptor on the cell 
membrane of skeletal muscle, thus enabling satellite cell activation (32). Importantly, 
however, high levels of HGF are not only associated with satellite cell activation, but 
also the up-regulation of myostatin (discussed below) mRNA, the product of which 
leads to satellite cell quiescence. These data suggest a fine regulatory role for HGF, 
distinct from IGF/mTOR signalling, in hypertrophy vs. self-renewal of skeletal 
muscle cells (33)*. Nitric oxide (NO) is also reportedly increased following 
mechanical stretch and leads to the up-regulation of matrix metalloproteinase activity, 
enabling matrix remodelling required to support hypertrophy (32). Indeed, 
overexpression of MMP-9 in C2C12 cell clones (C2M9) improves their migration in-
vitro and their engraftment in-vivo, both of which are required for hypertrophy and 
regeneration (34)*. β-catenin/c-Myc-signaling, important in ribosomal biogenesis, 
also increases following mechanical overload (load on the muscles, which leads to 
failure), with inactivation of β-catenin completely preventing hypertrophy in response 
to mechanical overload in mice (35). Indeed, hypertrophy induced in C2C12 myoblasts 
using both IGF-IEa and MGF increased nuclear β-catenin in-vitro (36) implicating a 
role for this molecule in potentially linking hypertrophy following IGF signalling 
and/or following a mechanical stimulus. 
 
 
 
 
9 
 
MicroRNAs at the Cutting Edge 
The class of approximately 22 nucleotide noncoding RNAs (microRNAs) that 
regulate gene expression at the post-transcriptional level may play fundamental roles 
in skeletal muscle hypertrophy. Recently, both miR-1 and miR-206 have been 
implicated in skeletal muscle cell differentiation. Overexpression in C2C12 myoblasts 
reduced proliferation and induced differentiation in-vitro (37)*. These miRNAs also 
function to control among other regulators, Pax7, which is required for appropriate 
satellite cell survival, proliferation, and differentiation. The role of miRNAs in a 
myoblast model of mechanical load requires further investigation. 
 
Summary: Myoblast Models of Hypertrophy 
Overall, the convergence of mechanical, endocrine, autocrine and pancrine signals 
results in activation of PI3K, Akt, mTOR leading to protein synthesis and hypertrophy 
via proliferation and differentiation of myoblasts, as well as corresponding ribosomal 
biogenesis through β-catenin/c-Myc-signaling. However, the relative contribution of 
each parameter, especially following mechanical load remains to be determined and 
has implications for therapeutic interventions aimed at improving hypertrophy during 
disease, ageing and following exercise. Finally, the importance of the implementation 
of 3-D myoblast models to study the integration of skeletal myoblasts with the ECM  
in-vitro, and to apply to situations of mechanical load/overload or stretch in-vivo are 
important for future developments in the field.  
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Muscle Atrophy: The Problem 
Skeletal muscle atrophy occurs when proteolysis overwhelms protein synthesis. 
Increased protein degradation may occur as a consequence of many factors, including 
changes in anabolic hormones e.g. IGF-I, GH, testosterone, glucocorticoids; and 
increases in TGF-β, myostatin, and cytokines such as TNF-α, TWEAK and IL-6. 
Oxidative stress and reduced amino acid availability can also tip the balance in favour 
of atrophy. Muscle wasting can occur as a consequence of: mechanical unloading, a 
reduction in use/exercise (disuse atrophy), chronic catabolic disease (cachexia) and 
ageing (sarcopenia). Even though resistance exercise may slow the atrophy process, 
many patients are too old, ill or simply unable (frail or obese) to exercise. 
Furthermore, resistance exercise has to be continually undertaken to be of long-term 
benefit, meaning high cost of skilled trainers and high drop-out due to its demanding 
physical nature. It is therefore important to also develop pharmalogical therapies to 
treat muscle atrophy. 
 
Myostatin and Atrophy 
It is beyond the scope of this review to discuss all factors that contribute to muscle 
atrophy (for excellent current reviews see (7, 38, 39)). However, recent in-vitro 
myoblast research has focussed on myostatin (growth differentiation factor- 8/GDF-
8). Myostatin is a member of the Transforming Growth Factor-Beta (TGF-β) family 
of proteins and a negative regulator of skeletal muscle growth. Pioneering work by 
McPherron and collegues (40, 41) using knock out technologies, demonstrated the 
important inhibitory role of myostatin in skeletal muscle of mice and also reported 
that the ‘double muscling’ phenotype in Belgian Blue and Piedmontese cattle 
occurred as a result of mutations in the myostatin gene (41). As a consequence, this 
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inhibitory growth factor has received a lot of attention as a potential therapeutic target 
to combat muscle wasting. Myostatin−/− mice that are crossed with follistatin 
transgenic mice display even larger muscle phenotypes as a result of blocking other 
inhibitory TGF-β family members such as GDF-11 and activins (42). However, the 
first human trial using low dose anti-myostatin antibodies in muscular dystrophy 
patients did not enable hypertrophy (43). However, this is a complex disease, where 
the underlying disorder is due to a lack of dystrophin rather than an increase in 
myostatin and it may not be the best model (44). 
 
Myostatin Signalling 
As a consequence of these data, mouse and rat myoblasts have been utilised to 
investigate the molecular mechanisms of myostatin in muscle. Myostatin reportedly 
blocks differentiation of myoblasts into myotubes (45) by reducing myoD (46), 
myogenin and protein synthetic pathways via Akt in C2C12 myotubes (47) and via 
Akt/TORC1/p70S6K in human skeletal myoblasts (48)**. Myostatin signals via the 
type IIb activin receptor that enables interactions with activin receptor-like-kinase 4 
(ALK4) or ALK5 (both type I receptors- see Figure 1) (49). As a consequence of the 
association of these myostatin/receptor complexes, phosphorylation of transcription 
factors Smad2 and Smad3 occurs followed by their translocation to the nucleus (50) 
where they alter gene transcription. Trendelenburg et al. (48)**, demonstrated that 
follistatin (myostatin inhibitor) and type I ALK receptor inhibitors increased both the 
size and number of human skeletal myoblasts in culture and, in the presence of 
exogenous myostatin were able to restore differentiation capacity. Furthermore, 
siRNAs for Smad 2 or 3 reduced the effect of myostatin on differentiation, with both 
in combination eliciting an additive effect. Interestingly, there was a 50% reduction in 
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phosphorylated Akt and p70S6K in the presence of myostatin in differentiating 
myoblasts and exogenous IGF-I could rescue this effect. However, IGF-I did not 
change Smad2/3 reporter activity indicating that IGF-I did not oppose myostatin 
actions via Smad, but via Akt and the induction of protein synthesis via p70S6K. 
Overall, therefore the IGF-I/Akt/protein synthesis signalling seems dominant over the 
myostatin/Smad inhibition. Conversely however, Smad 2 or 3 siRNAs restored Akt 
activation in the presence of myostatin, suggesting Smad2/3 do regulate Akt function 
but distinctly to IGF-I (48)**.   
 
A recent study by Satori et al. (51)** published simultaneously with that of 
Trendelenburg et al. (48)** showed that activation of the Smad 2 and 3 pathway 
using electroporation to introduce genes encoding active forms of ALK4 or 5 and 
TGF-β itself, induced myofibre atrophy. This effect could be reversed using small 
hairpin RNAs (shRNAs) blocking Smad2 and Smad3. Importantly, constitutive 
overexpression of Akt prevented the muscle fibre atrophy induced by Smad2/3 
activation (electroporation for ALK4 or 5 mentioned above), further co-borating the 
in-vitro role of Akt in reducing the impact of myostatin.  
 
Myostatin: Protein Synthesis or Protein Degradation? 
Some controversy remains over whether myostatin functions via traditional 
expression of “atrogenes” that promote protein degradation via E3 ubiquitin ligases 
such as MuRF1 and MAFbx. Early work strongly suggested that myostatin increased 
levels of FOXO1 that in turn up-regulated MAFbx (47) that leads to protein 
degradation of cytoskeletal proteins such as desmin and titin. Similarly in C2C12 
myoblasts the addition of myostatin increased MAFbx, but not MuRF1. Data were 
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confirmed in murine models where myostatin increased MAFbx but not MuRF1 
expression (51)**. By contrast, the study by Trendelenburg et al. (48)** reported a 
decrease in both MuRF1 and MAFbx mRNA. However, Welle (52) reviewed that 
neither publication included a direct measure of proteolysis,  however, that the vast 
majority of evidence suggests that changes in protein synthesis rather than 
degradation are key. Although compelling in-vitro/in-vivo signalling evidence 
suggests reduced protein synthesis, unresolved studies regarding the protein 
degradation remain.  Indeed, very recent findings suggesting that the in-vivo murine 
or in-vitro myoblast knockdown of MAFbx, using shRNAs, supresses myostatin 
expression and muscle atrophy (53)**, suggesting a feed-forward loop whereby 
increased MAFbx influences the local production and hence action of myostatin.  
 
Myostatin and Premature Ageing? 
Although myostain inhibitor studies have shown some success in reducing wasting in 
rodents (54, 55), myostatin inhibitors in human studies should be approached with 
care when considering regeneration with age. McFarlane et al. (56) showed that 
blocking myostatin, causes high Pax7 expression resulting in increased self-renewal 
of  C2C12 myoblasts followed by quiescence. However, they also reported that over 
expressing Pax7 in C2C12 cells conferred increased self-renewal but reduced 
myogenic proliferation and differentiation. Therefore, blocking myostatin in adults 
may be advantageous in the short-term; however, high expression of Pax7 would 
influence self-renewal and differentiation and potentially affect subsequent 
regeneration in later life. This may further compound ageing where myostatin levels 
are already higher than in younger individuals (57). Indeed, myostatin knock out 
animals, although displaying larger muscle mass, are not proportionally stronger (58), 
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this too would be detrimental, i.e. increased weight, but not strength to lift in older 
people.  
 
Conclusion 
Myoblast models have paved the way for understanding the convergence of key 
mechanisms involved in hypertrophy and atrophy of skeletal muscle; some of the 
most pertinent recent findings have been discussed in this review. However, future 
development of myoblast models must incorporate engineering strategies to make the 
models more reflective of the in-vivo situation and evolve the current 3-D models 
already available (8)**(9). In this way, cell-based models in a dish can be utilised to 
address key in-vitro questions, which can then be focussed to address more 
challenging in-vivo questions. 
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Figure Legend 
Figure 1. The regulation of protein synthesis and muscle hypertrophy vs. protein degradation and muscle atrophy.  
IGF-I; Insulin-like growth factor-I, IRS-1; Insulin Receptor Substrate-1, TNF-α; Tumour Necrosis Factor-Alpha, ALK 4, 5; Activin Receptor-
Like-Kinase 4 and Activin Receptor-Like-Kinase 5, ECM; Extracellular Matrix, HGF; Hepatocyte Growth Factor, TRADD; TNF Receptor 1 
Associated Death Domain, TRAFF; TNF receptor Associated Factor, FAK; Focal Adhesion Kinase, FADD; Fas Associated Death Domain, 
FOXO; Forkhead Homeobox Type O, PDK-1; Phosphoinositide-Dependent Kinase-1, Akt; Protein Kinase B, MAPK; Mitogen Activated 
Protein Kinase, mTOR; Mammalian Target of Rapamycin, PI3K; Phosphatidylinositol 3-kinase, ERK; Extra Cellular Signal Regulated Kinase, 
Ras; Ras Protein, Raf; MAP Kinase Kinase Kinase (MAP3K), p70S6K; P70S6 Kinase- a serine/threonine kinase- Phosphorylation of S6 induces 
protein synthesis at the ribosome, TSC1, TSC2; Tuberous Sclerosis Protein 1, Tuberous Sclerosis Protein 2, Redd 2; Regulated in Development 
and DNA Damage Response 2, Rheb; Ras Homolog Enriched in Brain, PLD; Phospholipase D, PA; Phosphatidic acid PA, I-κBα; Inhibitor-
Kappa B Alpha, NF-κB; Nuclear Factor-Kappa B, β-Catenin; Beta-Catenin. 
 
 
 
 
